DGAP-News: MAB Discovery GmbH: Synthon and MAB Discovery Sign Multi-Target Antibody Discovery Agreement

        Print
| Source: EQS Group AG
DGAP-News: MAB Discovery GmbH / Key word(s): Agreement
MAB Discovery GmbH: Synthon and MAB Discovery Sign Multi-Target
Antibody Discovery Agreement

06.05.2014 / 10:00

---------------------------------------------------------------------

Synthon and MAB Discovery Sign Multi-Target Antibody Discovery Agreement

Nijmegen, Netherlands and Neuried, Germany; May 6, 2014: Synthon
Biopharmaceuticals BV and MAB Discovery GmbH today announced the execution
of a research and license agreement. Under the terms of the agreement, MAB
Discovery will generate antibodies for targets selected by Synthon in
support of the company's development of antibody-drug conjugates (ADCs) and
alternative antibody-based therapeutics.

MAB Discovery will employ its in vivo antibody discovery technology
platform, which relies on the natural immune response of rabbits followed
by state-of-the-art B-cell cloning techniques. Using a novel
high-throughput screening route, MAB Discovery focuses on identifying
highly active antibodies with unprecedented epitope coverage, potency and
species cross-reactivity which has been successful for intractable targets.
This technology eliminates affinity maturation and surrogate development
which are very time-consuming and often sacrifice function.

Synthon will obtain high quality antibodies in support of their strategy to
create a portfolio of best-in-class antibody-based therapeutics, including
ADCs.

Additional details of the transaction were not disclosed.

- ENDS -

About Synthon

Synthon, with headquarters in Nijmegen, The Netherlands, is an
international pharmaceutical company and a leader in the field of generic
medicines. The company started its biopharmaceutical franchise in 2007 and
is building a promising portfolio of next generation medicines. Synthon is
developing rapidly into a specialty pharmaceutical company, focusing on the
therapeutic areas of auto-immune diseases and oncology. Synthon products
are currently approved by regulatory agencies in over 80 countries
worldwide and marketed through strategic partnerships and - in dedicated
areas - through direct sales. Synthon employs about 1,400 staff worldwide,
and in 2013 it recorded a turnover of EUR 215 million. For more
information, go to www.synthon.com.

About MAB Discovery

MAB Discovery was founded in Munich, Germany in October 2010. The team
represents a group of scientists out of Roche Biologicals R&D with
extensive experience in developing biologically based therapeutics. Funded
by PPD Inc., MAB Discovery follows a collaboration-based business model as
a basis for its partnerships. Because of their unique funding situation,
MAB Discovery can employ flexible business models to meet the needs of
their clients. For more information, go to www.mabdiscovery.com.

For more information please contact:

Synthon:    
Fabienne Douven    
Director Corporate Communications  
+31 24 372 7700    
mailto:fabienne.douven@synthon.com 

MAB Discovery:
Dr Birgit Zech
Vice President Business Development
+49 89 990 178-0
birgit.zech@mabdiscovery.com

For media inquiries:
MC Services AG
Raimund Gabriel
Phone: +49 89 210 228-30
raimund.gabriel@mc-services.eu


End of Corporate News

---------------------------------------------------------------------

06.05.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


266495 06.05.2014